Navigation Links
Micromet Closes $40 Million Private Equity Placement
Date:10/3/2008

registration requirements. Micromet, Inc. has agreed to file a registration statement with respect to the shares on or before November 3, 2008. This news release is being issued pursuant to and in accordance with Rule 135c under the Securities Act of 1933, as amended.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Four of its antibodies are currently in clinical trials, while the remainder of the product pipeline is in preclinical development. The BiTE(R) antibody blinatumomab (MT103/MEDI-538) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune system, to eliminate cancer cells. Micromet is developing blinatumomab in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. MT110 is the second BiTE antibody in clinical trials, and is being developed by Micromet in a phase 1 clinical trial for the treatment of patients with lung or gastrointestinal cancer. The third clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal antibody that targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The fourth clinical stage antibody is MT293 which is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. Three additional BiTE antibodies, targeting CD33, CEA and MCSP, respectively, are in preclinical
'/>"/>

SOURCE Micromet, Inc
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet to Present at Two Upcoming Investor Conferences
9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Clinverse, Inc. , a ... trials, today announced it will be exhibiting and ... in Boston, June 24-26, 2013. Clinverse’s eClinical ... fully configurable, cloud-based clinical financial lifecycle system. , ... Clinverse’s eClinical Commerce Network, automates site contract set-up ...
(Date:6/19/2013)... Calif. , June 19, 2013 ... plant, stool and other challenging microbial nucleic acid ... Protein Extraction Kit, for extraction of pure protein ... protein world coincides with the 20 th ... growing innovation capabilities. (Photo: http://photos.prnewswire.com/prnh/20130619/LA32633 ...
(Date:6/19/2013)... CLEVELAND , June 19, 2013   NineSigma ... announced that a year following its launch, NineSights.com ... and a focal point for the worldwide community of ... to climate and environmental sustainability experts, NineSights stands out ... broad range of scientific and technical disciplines, all vetted ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Today DuPont ... young people to become leaders in the greatest challenge ... billion people in 2050. Borel spoke at the ... Conference in Atlanta, about urgent need for students to ... are local, science-based, sustainable and reached in collaboration with ...
Breaking Biology Technology:Clinverse, Inc. Exhibiting and Showcasing Its Technology at DIA 2013 2MO BIO Laboratories, Inc. launches the first kit for protein extraction from soil 2NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 2NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 3DuPont Leader Calls for New Generation of Food Visionaries to Fight Hunger 2
... Purpose , ... this series describes an LC/MS/MS method for the simultaneous determination ... FK-506), Sirolimus (SIR, aka Rapamycin) and Everolimus (EVE, aka RAD-001) ... robust hardware configuration and shows to be fast and simple, ...
... , ... As the study of protein biomarkers increases in ... protein pathway information and discovery-based proteomics experiments. Even larger numbers of ... gene expression studies or other genomic information. , ...
... Purpose , ... non-nucleoside reverse transcriptase inhibitor (NNRTI) antiretroviral drugs is of significant ... metabolism variability. To be of practical use, it is essential ... fast and easy to perform, with minimal sample preparation, and ...
Cached Biology Technology:A new LC/MS/MS Research Method for Rapid Quantitation of Five Immunosuppressant Drugs, including Mycophenolic Acid (MPA) 2A new LC/MS/MS Research Method for Rapid Quantitation of Five Immunosuppressant Drugs, including Mycophenolic Acid (MPA) 3A new LC/MS/MS Research Method for Rapid Quantitation of Five Immunosuppressant Drugs, including Mycophenolic Acid (MPA) 4A new LC/MS/MS Research Method for Rapid Quantitation of Five Immunosuppressant Drugs, including Mycophenolic Acid (MPA) 5Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma 2Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma 3Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma 4Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma 5A simple and rapid LC-MS/MS method for the simultaneous determination of nine antiretroviral drugs commonly used in Europe (protease Inhibitors and non-nucleoside reverse transcriptase inhibitors) 2A simple and rapid LC-MS/MS method for the simultaneous determination of nine antiretroviral drugs commonly used in Europe (protease Inhibitors and non-nucleoside reverse transcriptase inhibitors) 3A simple and rapid LC-MS/MS method for the simultaneous determination of nine antiretroviral drugs commonly used in Europe (protease Inhibitors and non-nucleoside reverse transcriptase inhibitors) 4
(Date:6/19/2013)... Elsevier, a world-leading provider of scientific, technical and medical ... launch of a new open access journal, GeoResJ ... , Elsevier,s earth and planetary science journals portfolio has ... to provide a forum for rapid publication of top ... will be co-edited by six Executive Editors, each covering ...
(Date:6/18/2013)... the University of Calgary,s Faculty of Medicine have discovered ... from harmful bacteria. Platelets, a component of blood typically ... specific bacteria, and upon detection, seal it off from ... published in Nature Immunology this week, provide ... , "The science community has known that platelets do ...
(Date:6/18/2013)... environmental engineer has been awarded a $394,300 grant ... water quality and flow in the new facilities ... Kruzic, UT Arlington associate professor of civil engineering, ... add monochloramine to the water in an effort ... stations and pipelines. Adding monochloramine is widely practiced ...
Breaking Biology News(10 mins):Immunity mechanism discovered 2UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline 2
... orchids have been found to rely on a wide ... of the soil instead of producing their own organic ... the open access journal BMC Biology , also ... and Mlanie Roy, from the Centre d,Ecologie Fonctionnelle et ...
... Carnegie Mellon University have developed an analytical technique to ... disease syndromes such as diabetes, asthma and cancer, which ... Rather than searching one at a time for genetic ... as in most conventional approaches, the Carnegie Mellon scientists ...
... Water striders, the familiar semi-aquatic bugs gliding across the ... allows them to walk on water. This was not ... evolution of a unique arrangement of the legs, with the ... of Ecology and Evolutionary Biology have discovered the gene behind ...
Cached Biology News:Carnegie Mellon develops innovative method to detect genetic causes of complex diseases 2
... for quick and reproducible immunoprecipitation (IP) by using ... more reproducible than regular IPs, which are problematic ... without disrupting the agarose bed. The binding of ... reversible, and elution of the immune complex can ...
... Kit (V2), 2 x 11K will ... of many thousands of yeast genes ... biological processes. Each microarray contains sequences ... from the S288C strain of Saccharomyces ...
... require screening through a huge volume ... data from normal biologic diversity. The ... available to help better manage the ... inherent to biomarker discovery. The CiphergenExpress ...
... Immunoprecipitation kit allows a rapid and ... active FLAG-tagged protein. The immunoprecipitation is ... is a highly specific monoclonal antibody ... use of affinity resin allows an ...
Biology Products: